

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

Apple Tree Life Sciences, Inc., *et al.*,¹

Debtors.

Chapter 11

Case No. 25-12177 (LSS)

(Jointly Administered)

Re: Docket No. 134

**SUPPLEMENTAL DECLARATION OF HAROLD B. MURPHY IN SUPPORT OF
DEBTORS' APPLICATION FOR ENTRY OF AN ORDER
UNDER SECTIONS 327(a) AND 1107(b) OF THE BANKRUPTCY CODE,
BANKRUPTCY RULES 2014 AND 2016, AND LOCAL RULES 2014-1
AND 2016-1 AUTHORIZING RETENTION AND EMPLOYMENT OF
MURPHY & KING, PROFESSIONAL CORPORATION AS BANKRUPTCY
CO-COUNSEL FOR DEBTORS EFFECTIVE AS OF THE PETITION DATE**

I, Harold B. Murphy, under penalty of perjury, state as follows:

1. I am a shareholder in the law firm of Murphy & King, Professional Corporation (“M&K”), which maintains an office for the practice of law at 28 State Street, Suite 3101, Boston, MA 02109. I am an attorney at law, duly admitted and in good standing to practice in the Commonwealth of Massachusetts and in the United States District Court for the District of Massachusetts, and I am admitted *pro hac vice* in the above-captioned proceedings.

2. I make this supplemental declaration (this “Supplemental Declaration”) in further support of the *Debtors' Application for Entry of an Order Under Sections 327(a) and 1107(b) of the Bankruptcy Code, Bankruptcy Rules 2014 and 2016, and Local Rules 2014-1 and 2016-1*

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Square Therapeutics, Inc. (4503); and Nereid Therapeutics Incorporated (8493). The location of the Debtors' service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.



Authorizing Retention and Employment of Murphy & King, Professional Corporation as Bankruptcy Co-Counsel for Debtors Effective as of the Petition Date (the “Application”)² to provide certain disclosures in accordance with the Bankruptcy Code, the Bankruptcy Rules, and the Local Rules.

3. Attached to the Application as Exhibit B was the *Declaration of Harold B. Murphy in Support of the Debtors’ Application for Entry of an Order Under Sections 327(a) and 1107(b) of the Bankruptcy Code, Bankruptcy Rules 2014 and 2016, and Local Rules 2014-1 and 2016-1 Authorizing Retention and Employment of Murphy & King, Professional Corporation as Bankruptcy Co-Counsel for Debtors Effective as of the Petition Date* (the “Initial Declaration”). This Supplemental Declaration supplements the Initial Declaration.

4. Attached to the Initial Declaration as Schedule 1 was a list of potential parties in interest in these Chapter 11 Cases. Subsequent to the filing of the Initial Declaration, the Debtors made M&K aware of certain additional parties in interest (the “Additional Parties in Interest”), a list of whom is attached hereto as Exhibit 1.

5. I caused to be submitted the names of the Additional Parties in Interest for review under the conflict check system maintained by M&K. M&K professionals working under my supervision then compared the names of the Additional Parties in Interest to the names that M&K has compiled into its conflict check system and adverse party index. No matches between M&K’s conflict check system and the Additional Parties in Interest were identified. Therefore, M&K has no additional disclosures to make at this time.

² Capitalized terms used but not otherwise defined herein shall have the respective meanings set forth in the Application.

6. M&K will amend this statement or the Initial Declaration upon learning that (i) any of the within representations are no longer correct or (ii) there is any material change of circumstance requiring additional disclosure.

Pursuant to 28 U.S.C. § 1746, I declare under penalty of perjury that the foregoing is true and correct to the best of my knowledge and belief.

Date: February 18, 2026

/s/ Harold B. Murphy
Harold B. Murphy

Exhibit 1

Additional Parties in Interest

Rigmora Counsel

Debevoise & Plimpton LLP
Richards Layton & Finger P.A.

DIP Lender Parties

Alter Domus (US) LLC
Cleary Gottlieb Steen & Hamilton LLP
Oak Tree Capital Management, Inc.

Ordinary Course Professionals

Covington & Burling LLP
DiFilippo Corporate Finance Group
Elsberg Baker & Maruri PLLC
Mishcon De Reya LLP (UK)
Stout Risius Ross, LLC

Committee Professionals

Cole Schotz P.C.
Dundon Advisors LLC

Nereid Therapeutics Equity Holders

Alice Ting
Bahareh Eftekharzadeh
Chanelle Jumper
Cigall Kadoch
Dr. Clifford Brangwynne
Eugene Lee
Defne Yarar
Ivan Efremov
Jared Toettcher
John Reilly
Dr. Laura Forese
Robert Hugin

Nereid Therapeutics Top 20 Unsecured

Creditors

AustinPX LLC
Crelux GmbH
Crystal Pharmatech Co., Ltd.
Evotec US
Nexomics BioSciences
Oncolines
Premier Research Consulting, LLC
RREF II 451D, LLC
STA Pharmaceutical Hong Kong Limited
VectorBuilder, Inc.

**Non-Debtor Portfolio Company Directors
and Officers**

Andrew Geall
Ankeet Jethwa
Anna Batarina
Antoine Papiernik
Aron Knickernocker
Brian Shoichet
Christopher Rader
David Lewis
Dennis Langer
Doug Godshall
Edward Yoon
Himani Bhalla
Jerry Karabelas
Jim Vaselli
Kathy Fernando
Leo Redmund
Mace Rothbenberg
Micheal Derkacz
Micheal Ehlers
Micheal Wasserman
Mikael Dolsten
Nathaniel Wang